SCHEDULE A — LICENSED PATENTS
Schedule A to the Exclusive License Agreement dated October 2, 2023 (effective October 20, 2023)
between
Penterra Pharmaceuticals Corp. a Delaware corporation ("Licensor")
and
Meridian Bio Therapeutics Limited a Hong Kong limited company ("Licensee")
Compound: PPC-4187 (Penteracitinib)
This Schedule A is attached to and incorporated by reference into the Exclusive License Agreement (the "Agreement") between Penterra Pharmaceuticals Corp., a Delaware corporation ("Licensor"), and Meridian Bio Therapeutics Limited, a Hong Kong limited company ("Licensee"), dated October 2, 2023, with an Effective Date of October 20, 2023. Capitalized terms not otherwise defined herein shall have the meanings ascribed to them in the Agreement.
Patent prosecution counsel for the Licensed Patents identified herein is Whitford & Cascade Insurance Brokers (Dr. Alan J. Whitford, Lead Patent Attorney), 1750 K Street NW, Suite 600, Washington, DC 20006. All references to prosecution coordination herein are to the activities of such counsel, unless otherwise stated.
Section 1: Overview of Licensed Patent Portfolio
The Licensed Patents licensed to Licensee under the Agreement consist of seven (7) patent families covering the following subject matter areas relating to the compound designated PPC-4187 (Penteracitinib):
The Licensed Patents include all patents and patent applications listed below in Sections 2 through 8 of this Schedule A, together with all continuations, continuations-in-part, divisionals, reissues, reexaminations, patent term extensions, supplementary protection certificates, and any foreign counterparts thereof in the Territory. The Licensed Patents further include any patents or patent applications that claim priority to, or share a common priority date with, the patents and patent applications listed herein, to the extent such patents or patent applications are filed in or cover a jurisdiction within the Territory.
The Territory is defined in Schedule D to the Agreement and comprises the following jurisdictions: the People's Republic of China (including Hong Kong Special Administrative Region and Macau Special Administrative Region), Japan, the Republic of Korea, Australia, New Zealand, Singapore, Thailand, Malaysia, Indonesia, the Philippines, Vietnam, and Taiwan.
For each Patent Family, patents and patent applications in the United States are listed for completeness and cross-reference purposes only. United States patents are retained by Licensor for use in the Retained Territory and are not licensed to Licensee for exploitation in the United States; however, such United States patents are included in this Schedule A solely for the purposes of the cross-license-back and patent coordination provisions of Article 12 of the Agreement.
Section 2: Patent Family 1 — Composition of Matter
Description: Patent Family 1 covers the novel chemical compound PPC-4187 (Penteracitinib), a selective Janus kinase 1 (JAK1) inhibitor, including its free base, pharmaceutically acceptable salts (including, without limitation, hydrochloride, mesylate, tosylate, fumarate, and tartrate salts), solvates, hydrates, polymorphs, and prodrugs thereof. This patent family provides the foundational intellectual property protection for the PPC-4187 compound and is the primary composition-of-matter patent family in the Licensed Patent portfolio.
PCT Application: PCT/US2019/045123, International Filing Date: July 15, 2019, Applicant: Penterra Pharmaceuticals Corp. National phase entries have been completed in each of the jurisdictions listed below.
2.1 United States
Note: This United States patent is a Retained Territory patent. It is included in this Schedule A solely for purposes of the cross-license-back and patent coordination provisions of Article 12 of the Agreement. U.S. Patent No. 11,234,567 is not licensed to Licensee for use in the United States or any jurisdiction outside the Territory, but is listed for completeness and cross-reference.
2.2 People's Republic of China
Prosecution of this patent was handled by Whitford & Cascade Insurance Brokers in coordination with local PRC patent agent, Zhonghui Patent & Trademark Agency (Beijing). The granted claims include twenty-three (23) claims covering the compound PPC-4187 in free base form and as pharmaceutically acceptable salts thereof.
2.3 Japan.
2.4 Republic of Korea
2.5 Australia.
2.6 New Zealand
2.7 Singapore.
2.8 Thailand.
2.9 Malaysia.
2.10 Indonesia.
2.11 Philippines.
2.12 Vietnam.
2.13 Taiwan.
Section 3: Patent Family 2 — Crystalline Forms
Description: Patent Family 2 covers Crystalline Form A of PPC-4187 (Penteracitinib), including its characterization by X-ray powder diffraction (XRPD) pattern, differential scanning calorimetry (DSC), thermogravimetric analysis (TGA), and other solid-state characterization data. The claims in this patent family cover Crystalline Form A as characterized by specific 2-theta values in the XRPD pattern, processes for preparing Crystalline Form A, and pharmaceutical compositions comprising Crystalline Form A.
3.1 United States
Note: This United States patent is a Retained Territory patent. It is listed in this Schedule A for completeness and cross-reference purposes only, per the provisions of Article 12 of the Agreement.
3.2 Territory National Phase Entries
National phase entries from the corresponding PCT application (PCT/US2020/058901, International Filing Date: November 3, 2020) have been filed in each of the Territory jurisdictions listed below. As of the Effective Date, all Territory national phase applications for Patent Family 2 remain pending unless otherwise noted.
All applications listed above are assigned to Penterra Pharmaceuticals Corp. Prosecution in each Territory jurisdiction is coordinated by Whitford & Cascade Insurance Brokers (Dr. Alan J. Whitford) in consultation with local patent agents and counsel in each respective jurisdiction.
Section 4: Patent Family 3 — Methods of Use
Description: Patent Family 3 covers methods of treating moderate-to-severe atopic dermatitis in adult patients using PPC-4187 (Penteracitinib), including dosage-specific method claims for 25 mg and 50 mg once-daily oral administration. The claims in this patent family are supported by clinical data from Study PPC-4187-201, a multi-center, randomized, double-blind, placebo-controlled Phase IIb clinical trial enrolling 420 patients, which demonstrated an EASI-75 response at Week 16 with statistical significance (p<0.001 vs. placebo). Study PPC-4187-201 was completed in June 2023.
The corresponding PCT application for this family is PCT/US2021/034567, with an International Filing Date of May 28, 2021. National phase entries have been completed in the United States and in each Territory jurisdiction as set forth below.
4.1 Jurisdiction Table
*United States application listed for cross-reference and patent coordination purposes only pursuant to Article 12 of the Agreement. Not licensed to Licensee for use in the United States.
All applications listed above are assigned to Penterra Pharmaceuticals Corp. All expiration dates stated above are expected expiration dates, assuming grant, and are calculated before any patent term extension, patent term adjustment, supplementary protection certificate, or equivalent extension.
Section 5: Patent Family 4 — Pharmaceutical Formulations
Description: Patent Family 4 covers oral pharmaceutical compositions comprising PPC-4187 (Penteracitinib), including film-coated tablet formulations at 25 mg and 50 mg dosage strengths, and specific excipient combinations including microcrystalline cellulose, lactose monohydrate, croscarmellose sodium, magnesium stearate, and an Thackeray Systems® II film coating system. Claims in this patent family encompass the finished dosage form, methods of preparing the dosage form, and the combination of excipients with PPC-4187 in specified proportions.
The corresponding PCT application for this family is PCT/US2021/041234, with an International Filing Date of July 12, 2021. National phase entries have been completed in the United States and in each Territory jurisdiction as set forth below.
5.1 Jurisdiction Table
*United States application listed for cross-reference and patent coordination purposes only pursuant to Article 12 of the Agreement. Not licensed to Licensee for use in the United States.
All applications listed above are assigned to Penterra Pharmaceuticals Corp. All expiration dates stated above are expected expiration dates, assuming grant, and are calculated before any patent term extension, patent term adjustment, supplementary protection certificate, or equivalent extension.
Section 6: Patent Family 5 — Manufacturing Process
Description: Patent Family 5 covers proprietary manufacturing processes for the synthesis and purification of PPC-4187 (Penteracitinib) active pharmaceutical ingredient (API), including key synthetic intermediates, catalytic coupling reactions, crystallization conditions, and critical process parameters for commercial-scale manufacturing. The manufacturing process described in this patent family has been validated at Alkerra Manufacturing Inc., 5200 Meridian Parkway, Research Triangle Park, NC 27713, pursuant to current Good Manufacturing Practice (cGMP) requirements.
The corresponding PCT application for this family is PCT/US2021/048901, with an International Filing Date of September 3, 2021. National phase entries have been completed in the United States and in each Territory jurisdiction as set forth below.
6.1 Jurisdiction Table
*United States application listed for cross-reference and patent coordination purposes only pursuant to Article 12 of the Agreement. Not licensed to Licensee for use in the United States.
All applications listed above are assigned to Penterra Pharmaceuticals Corp. All expiration dates stated above are expected expiration dates, assuming grant, and are calculated before any patent term extension, patent term adjustment, supplementary protection certificate, or equivalent extension.
Section 7: Patent Family 6 — Combination Therapy
Description: Patent Family 6 covers methods and compositions for administering PPC-4187 (Penteracitinib) in combination with other therapeutic agents for the treatment of atopic dermatitis and related inflammatory conditions. Specifically, the claims encompass the co-administration of PPC-4187 with one or more topical corticosteroids, topical calcineurin inhibitors, phosphodiesterase-4 (PDE4) inhibitors, or biologic agents targeting interleukin-4 (IL-4), interleukin-13 (IL-13), or interleukin-31 (IL-31) pathways, in patients with moderate-to-severe atopic dermatitis.
The corresponding PCT application for this family is PCT/US2022/012345, with an International Filing Date of January 14, 2022. National phase entries have been completed in the United States and in each Territory jurisdiction as set forth below.
7.1 Jurisdiction Table
*United States application listed for cross-reference and patent coordination purposes only pursuant to Article 12 of the Agreement. Not licensed to Licensee for use in the United States.
All applications listed above are assigned to Penterra Pharmaceuticals Corp. All expiration dates stated above are expected expiration dates, assuming grant, and are calculated before any patent term extension, patent term adjustment, supplementary protection certificate, or equivalent extension.
Section 8: Patent Family 7 — Dosage Regimen
Description: Patent Family 7 covers specific dosage regimens for once-daily oral administration of PPC-4187 (Penteracitinib) at specified dose levels for the treatment of moderate-to-severe atopic dermatitis, including titration protocols (e.g., initiation at 25 mg once daily for two weeks followed by escalation to 50 mg once daily), patient selection criteria based on baseline disease severity (Eczema Area and Severity Index score ≥16 and Investigator's Global Assessment score ≥3), and dose adjustment criteria for patients with hepatic or renal impairment.
The corresponding PCT application for this family is PCT/US2022/025678, with an International Filing Date of April 22, 2022. National phase entries have been completed in the United States and in each Territory jurisdiction as set forth below.
8.1 Jurisdiction Table
*United States application listed for cross-reference and patent coordination purposes only pursuant to Article 12 of the Agreement. Not licensed to Licensee for use in the United States.
All applications listed above are assigned to Penterra Pharmaceuticals Corp. All expiration dates stated above are expected expiration dates, assuming grant, and are calculated before any patent term extension, patent term adjustment, supplementary protection certificate, or equivalent extension.
Section 9: Summary Table — All Licensed Patents
The following consolidated summary table lists all patents and patent applications across all seven (7) patent families and all jurisdictions. Entries marked with an asterisk (*) under the "Jurisdiction" column denote United States patents and applications that are listed for cross-reference and patent coordination purposes only pursuant to Article 12 of the Agreement and are not licensed to Licensee for exploitation in the United States.
The total portfolio as of the Effective Date comprises seven (7) patent families filed across up to thirteen (13) jurisdictions (the United States plus twelve (12) Territory jurisdictions), for a maximum of ninety-one (91) entries. As of the Effective Date, certain patent families have not yet been filed in all Territory jurisdictions; the table below reflects the actual filings as of October 20, 2023.
Entries marked with an asterisk () are United States patents or patent applications retained by Licensor for the Retained Territory and are listed solely for cross-reference and patent coordination purposes under Article 12 of the Agreement. "Penterra" refers to Penterra Pharmaceuticals Corp. All expiration dates are stated before any applicable patent term extension, patent term adjustment, supplementary protection certificate, or equivalent extension.
Section 10: PCT Applications
The following PCT applications serve as the basis for the national phase entries in the Licensed Patent portfolio:
In each case, national phase entries from the respective PCT applications have been filed in the United States and in each of the Territory jurisdictions identified in Sections 2 through 8 above and in the Summary Table in Section 9 above. The PCT applications themselves are no longer pending, having served their purpose as the basis for national and regional phase entries.
Section 11: Notes and Qualifications
11.1 Expiration Dates. All expiration dates set forth in this Schedule A are stated before any patent term extension ("PTE"), patent term adjustment ("PTA"), supplementary protection certificate ("SPC"), or equivalent extension that may be available under the applicable laws of the relevant jurisdiction. To the extent that any PTE, PTA, SPC, or equivalent extension is obtained for any Licensed Patent, the expiration date of such Licensed Patent shall be deemed extended accordingly for all purposes under the Agreement, and this Schedule A shall be updated to reflect such extension in accordance with Section 11.5 below.
11.2 Pending Applications. Pending patent applications listed in this Schedule A are subject to examination by the relevant patent office in each jurisdiction and may not result in granted patents. The scope of any claims that may ultimately be granted may differ from the claims as filed. Licensor makes no warranty or representation that any pending application will be granted or that the claims of any pending application will be granted in the form currently pending. The representations and warranties of Licensor regarding the Licensed Patents, including with respect to validity, enforceability, ownership, and freedom from encumbrances, are set forth exclusively in Article 9 of the Agreement, and nothing in this Schedule A shall be construed to expand or modify such representations and warranties.
11.3 Joint Patent Committee. The Joint Patent Committee ("JPC"), comprised of two (2) representatives designated by Licensor and two (2) representatives designated by Licensee, shall oversee the prosecution, maintenance, defense, and enforcement of the Licensed Patents in the Territory, as more fully set forth in Article 12 of the Agreement. The JPC shall meet not less frequently than quarterly and shall coordinate all material prosecution and enforcement decisions relating to the Licensed Patents in the Territory, including the filing of responses to office actions, the initiation or defense of opposition, invalidation, or revocation proceedings, and the pursuit of any patent term extensions or supplementary protection certificates.
11.4 Patent Prosecution Coordination. Patent prosecution for the Licensed Patents in the Territory is coordinated by Whitford & Cascade Insurance Brokers (Dr. Alan J. Whitford, Lead Patent Attorney), in consultation with local counsel and patent agents in each Territory jurisdiction. The selection and retention of local counsel and patent agents in each jurisdiction shall be subject to the mutual agreement of the parties through the JPC, as provided in Article 12 of the Agreement. Licensor shall bear all costs and expenses of prosecution and maintenance of the Licensed Patents in the United States; Licensee shall bear all costs and expenses of prosecution and maintenance of the Licensed Patents in the Territory, in each case as more fully described in Section 12.4 of the Agreement.
11.5 Updates to Schedule A. This Schedule A shall be updated from time to time by mutual written agreement of the parties to reflect (a) newly granted patents (including the grant date, patent number, and scope of granted claims), (b) newly filed patent applications (including continuations, continuations-in-part, divisionals, and new national phase entries), (c) any changes in the status of any Listed Patent or patent application (including abandonment, withdrawal, lapse, revocation, invalidation, or expiration), (d) any patent term extensions, patent term adjustments, supplementary protection certificates, or equivalent extensions obtained, and (e) any assignments or changes in ownership. Updates to this Schedule A shall be made in accordance with Section 14.8 of the Agreement and shall not require a formal amendment to the Agreement, provided that both parties have consented in writing to the updated Schedule A.
11.6 Royalty Term. The royalty term under the Agreement is, on a country-by-country and product-by-product basis, the period commencing on the date of first commercial sale of a Licensed Product in such country and ending on the later of (a) the expiration of the last-to-expire Valid Claim of a Licensed Patent covering such Licensed Product in such country, or (b) twelve (12) years from the date of first commercial sale of such Licensed Product in such country, as more fully described in Section 7.3 of the Agreement. Following expiration of the royalty term in a given country, the license granted to Licensee under the Agreement with respect to such country shall become a fully paid-up, irrevocable, perpetual, non-exclusive license, as set forth in Section 7.4 of the Agreement.
— End of Schedule A —
Cross-References:
This Schedule A should be read in conjunction with the following additional Schedules to the Agreement:
• Schedule B — Licensed Know-How
• Schedule C — Licensed Trademarks
• Schedule D — Territory
Each of the foregoing Schedules is attached to and incorporated by reference into the Agreement between Penterra Pharmaceuticals Corp. and Meridian Bio Therapeutics Limited, dated October 2, 2023 (Effective Date: October 20, 2023).
As of the Effective Date: October 20, 2023. This Schedule A is confidential and subject to the confidentiality provisions set forth in Article 13 of the Agreement.
| Patent Family No. | Subject Matter |
| Family 1 | Composition of Matter |
| Family 2 | Crystalline Forms (Form A) |
| Family 3 | Methods of Use (Treatment of Atopic Dermatitis) |
| Family 4 | Pharmaceutical Formulations |
| Family 5 | Manufacturing Process |
| Family 6 | Combination Therapy |
| Family 7 | Dosage Regimen |
| Field | Detail |
| Patent No. | 11,234,567 |
| Title | Selective JAK1 Inhibitor Compounds and Pharmaceutically Acceptable Salts Thereof |
| Filing Date | July 15, 2019 (national phase entry from PCT/US2019/045123) |
| Grant Date | January 25, 2022 |
| Expiration Date | August 12, 2037 (before any patent term extension or patent term adjustment) |
| Status | Granted |
| Assignee | Penterra Pharmaceuticals Corp. |
| Field | Detail |
| Patent No. | ZL 2020 1 0456789.0 |
| Title | Selective JAK1 Inhibitor Compounds and Pharmaceutically Acceptable Salts Thereof |
| Filing Date | January 14, 2020 (national phase entry from PCT/US2019/045123) |
| Grant Date | September 8, 2023 |
| Expiration Date | August 12, 2037 |
| Status | Granted |
| Assignee | Penterra Pharmaceuticals Corp. |
| Field | Detail |
| Patent No. | 7,012,345 |
| Title | Selective JAK1 Inhibitor Compounds and Pharmaceutically Acceptable Salts Thereof |
| Filing Date | January 15, 2020 (national phase entry from PCT/US2019/045123) |
| Grant Date | June 23, 2023 |
| Expiration Date | August 12, 2037 |
| Status | Granted |
| Assignee | Penterra Pharmaceuticals Corp. |
| Field | Detail |
| Patent No. | 10-2345678 |
| Title | Selective JAK1 Inhibitor Compounds and Pharmaceutically Acceptable Salts Thereof |
| Filing Date | January 14, 2020 (national phase entry from PCT/US2019/045123) |
| Grant Date | August 4, 2023 |
| Expiration Date | August 12, 2037 |
| Status | Granted |
| Assignee | Penterra Pharmaceuticals Corp. |
| Field | Detail |
| Patent No. | 2020234567 |
| Title | Selective JAK1 Inhibitor Compounds and Pharmaceutically Acceptable Salts Thereof |
| Filing Date | January 15, 2020 (national phase entry from PCT/US2019/045123) |
| Grant Date | March 17, 2023 |
| Expiration Date | August 12, 2037 |
| Status | Granted |
| Assignee | Penterra Pharmaceuticals Corp. |
| Field | Detail |
| Application No. | 773456 |
| Title | Selective JAK1 Inhibitor Compounds and Pharmaceutically Acceptable Salts Thereof |
| Filing Date | January 15, 2020 (national phase entry from PCT/US2019/045123) |
| Grant Date | July 28, 2023 |
| Expiration Date | August 12, 2037 |
| Status | Granted |
| Assignee | Penterra Pharmaceuticals Corp. |
| Field | Detail |
| Application No. | 11202000456T |
| Title | Selective JAK1 Inhibitor Compounds and Pharmaceutically Acceptable Salts Thereof |
| Filing Date | January 14, 2020 (national phase entry from PCT/US2019/045123) |
| Expected Expiration Date | August 12, 2037 (if granted) |
| Status | Pending |
| Assignee | Penterra Pharmaceuticals Corp. |
| Field | Detail |
| Application No. | 2001000345 |
| Title | Selective JAK1 Inhibitor Compounds and Pharmaceutically Acceptable Salts Thereof |
| Filing Date | January 15, 2020 (national phase entry from PCT/US2019/045123) |
| Expected Expiration Date | August 12, 2037 (if granted) |
| Status | Pending |
| Assignee | Penterra Pharmaceuticals Corp. |
| Field | Detail |
| Application No. | PI2020000789 |
| Title | Selective JAK1 Inhibitor Compounds and Pharmaceutically Acceptable Salts Thereof |
| Filing Date | January 15, 2020 (national phase entry from PCT/US2019/045123) |
| Expected Expiration Date | August 12, 2037 (if granted) |
| Status | Pending |
| Assignee | Penterra Pharmaceuticals Corp. |
| Field | Detail |
| Application No. | P00202000567 |
| Title | Selective JAK1 Inhibitor Compounds and Pharmaceutically Acceptable Salts Thereof |
| Filing Date | January 15, 2020 (national phase entry from PCT/US2019/045123) |
| Expected Expiration Date | August 12, 2037 (if granted) |
| Status | Pending |
| Assignee | Penterra Pharmaceuticals Corp. |
| Field | Detail |
| Application No. | 1-2020-500123 |
| Title | Selective JAK1 Inhibitor Compounds and Pharmaceutically Acceptable Salts Thereof |
| Filing Date | January 14, 2020 (national phase entry from PCT/US2019/045123) |
| Expected Expiration Date | August 12, 2037 (if granted) |
| Status | Pending |
| Assignee | Penterra Pharmaceuticals Corp. |
| Field | Detail |
| Application No. | 1-2020-00234 |
| Title | Selective JAK1 Inhibitor Compounds and Pharmaceutically Acceptable Salts Thereof |
| Filing Date | January 15, 2020 (national phase entry from PCT/US2019/045123) |
| Expected Expiration Date | August 12, 2037 (if granted) |
| Status | Pending |
| Assignee | Penterra Pharmaceuticals Corp. |
| Field | Detail |
| Application No. | 109101234 |
| Title | Selective JAK1 Inhibitor Compounds and Pharmaceutically Acceptable Salts Thereof |
| Filing Date | January 14, 2020 (national phase entry from PCT/US2019/045123) |
| Expected Expiration Date | August 12, 2037 (if granted) |
| Status | Pending |
| Assignee | Penterra Pharmaceuticals Corp. |
| Field | Detail |
| Patent No. | 11,345,678 |
| Title | Crystalline Forms of a Selective JAK1 Inhibitor |
| Filing Date | November 3, 2020 |
| Grant Date | May 16, 2023 |
| Expiration Date | November 3, 2038 (before any patent term extension or patent term adjustment) |
| Status | Granted |
| Assignee | Penterra Pharmaceuticals Corp. |
| Jurisdiction | Application No. | Filing Date | Grant Date | Expected Expiration | Status |
| People's Republic of China | CN 202180012345.6 | May 2, 2022 | — | November 3, 2038 | Pending |
| Japan | JP 2022-527891 | May 3, 2022 | — | November 3, 2038 | Pending |
| Republic of Korea | KR 10-2022-7013456 | May 2, 2022 | — | November 3, 2038 | Pending |
| Australia | AU 2021367890 | May 3, 2022 | — | November 3, 2038 | Pending |
| New Zealand | NZ 789012 | May 3, 2022 | — | November 3, 2038 | Pending |
| Singapore | SG 11202204567X | May 2, 2022 | — | November 3, 2038 | Pending |
| Thailand | TH 2201001234 | May 3, 2022 | — | November 3, 2038 | Pending |
| Malaysia | MY PI2022002345 | May 3, 2022 | — | November 3, 2038 | Pending |
| Indonesia | ID P00202203456 | May 3, 2022 | — | November 3, 2038 | Pending |
| Philippines | PH 1-2022-550234 | May 2, 2022 | — | November 3, 2038 | Pending |
| Vietnam | VN 1-2022-02345 | May 3, 2022 | — | November 3, 2038 | Pending |
| Taiwan | TW 111116789 | May 2, 2022 | — | November 3, 2038 | Pending |
| Jurisdiction | Patent/Application No. | Filing Date | Grant Date | Expiration Date | Status |
| United States* | 17/456,789 | November 28, 2022 | — | May 28, 2039 | Pending |
| People's Republic of China | CN 202280023456.7 | November 25, 2022 | — | May 28, 2039 | Pending |
| Japan | JP 2023-572345 | November 28, 2022 | — | May 28, 2039 | Pending |
| Republic of Korea | KR 10-2023-7030123 | November 25, 2022 | — | May 28, 2039 | Pending |
| Australia | AU 2022278901 | November 28, 2022 | — | May 28, 2039 | Pending |
| New Zealand | NZ 801234 | November 28, 2022 | — | May 28, 2039 | Pending |
| Singapore | SG 11202212345A | November 25, 2022 | — | May 28, 2039 | Pending |
| Thailand | TH 2201003456 | November 28, 2022 | — | May 28, 2039 | Pending |
| Malaysia | MY PI2022006789 | November 28, 2022 | — | May 28, 2039 | Pending |
| Indonesia | ID P00202209012 | November 28, 2022 | — | May 28, 2039 | Pending |
| Philippines | PH 1-2022-551234 | November 25, 2022 | — | May 28, 2039 | Pending |
| Vietnam | VN 1-2022-05678 | November 28, 2022 | — | May 28, 2039 | Pending |
| Taiwan | TW 111143210 | November 25, 2022 | — | May 28, 2039 | Pending |
| Jurisdiction | Patent/Application No. | Filing Date | Grant Date | Expiration Date | Status |
| United States* | 17/512,345 | January 10, 2023 | — | July 12, 2039 | Pending |
| People's Republic of China | CN 202280034567.8 | January 8, 2023 | — | July 12, 2039 | Pending |
| Japan | JP 2024-501234 | January 10, 2023 | — | July 12, 2039 | Pending |
| Republic of Korea | KR 10-2024-7001234 | January 8, 2023 | — | July 12, 2039 | Pending |
| Australia | AU 2022312345 | January 10, 2023 | — | July 12, 2039 | Pending |
| New Zealand | NZ 812345 | January 10, 2023 | — | July 12, 2039 | Pending |
| Singapore | SG 11202300123W | January 8, 2023 | — | July 12, 2039 | Pending |
| Thailand | TH 2301000567 | January 10, 2023 | — | July 12, 2039 | Pending |
| Malaysia | MY PI2023000234 | January 10, 2023 | — | July 12, 2039 | Pending |
| Indonesia | ID P00202300456 | January 10, 2023 | — | July 12, 2039 | Pending |
| Philippines | PH 1-2023-550012 | January 8, 2023 | — | July 12, 2039 | Pending |
| Vietnam | VN 1-2023-00123 | January 10, 2023 | — | July 12, 2039 | Pending |
| Taiwan | TW 112100345 | January 8, 2023 | — | July 12, 2039 | Pending |
| Jurisdiction | Patent/Application No. | Filing Date | Grant Date | Expiration Date | Status |
| United States* | 17/534,567 | March 3, 2023 | — | September 3, 2039 | Pending |
| People's Republic of China | CN 202280045678.9 | March 1, 2023 | — | September 3, 2039 | Pending |
| Japan | JP 2024-512345 | March 3, 2023 | — | September 3, 2039 | Pending |
| Republic of Korea | KR 10-2024-7008901 | March 1, 2023 | — | September 3, 2039 | Pending |
| Australia | AU 2022345678 | March 3, 2023 | — | September 3, 2039 | Pending |
| New Zealand | NZ 823456 | March 3, 2023 | — | September 3, 2039 | Pending |
| Singapore | SG 11202301234Y | March 1, 2023 | — | September 3, 2039 | Pending |
| Thailand | TH 2301002345 | March 3, 2023 | — | September 3, 2039 | Pending |
| Malaysia | MY PI2023001567 | March 3, 2023 | — | September 3, 2039 | Pending |
| Indonesia | ID P00202301890 | March 3, 2023 | — | September 3, 2039 | Pending |
| Philippines | PH 1-2023-550345 | March 1, 2023 | — | September 3, 2039 | Pending |
| Vietnam | VN 1-2023-01456 | March 3, 2023 | — | September 3, 2039 | Pending |
| Taiwan | TW 112107890 | March 1, 2023 | — | September 3, 2039 | Pending |
| Jurisdiction | Patent/Application No. | Filing Date | Grant Date | Expiration Date | Status |
| United States* | 18/156,789 | July 12, 2023 | — | January 14, 2040 | Pending |
| People's Republic of China | CN 202380012345.0 | July 10, 2023 | — | January 14, 2040 | Pending |
| Japan | JP 2024-534567 | July 12, 2023 | — | January 14, 2040 | Pending |
| Republic of Korea | KR 10-2024-7018901 | July 10, 2023 | — | January 14, 2040 | Pending |
| Australia | AU 2023201234 | July 12, 2023 | — | January 14, 2040 | Pending |
| New Zealand | NZ 834567 | July 12, 2023 | — | January 14, 2040 | Pending |
| Singapore | SG 11202306789Z | July 10, 2023 | — | January 14, 2040 | Pending |
| Thailand | TH 2301005678 | July 12, 2023 | — | January 14, 2040 | Pending |
| Malaysia | MY PI2023004567 | July 12, 2023 | — | January 14, 2040 | Pending |
| Indonesia | ID P00202305678 | July 12, 2023 | — | January 14, 2040 | Pending |
| Philippines | PH 1-2023-551234 | July 10, 2023 | — | January 14, 2040 | Pending |
| Vietnam | VN 1-2023-04567 | July 12, 2023 | — | January 14, 2040 | Pending |
| Taiwan | TW 112125678 | July 10, 2023 | — | January 14, 2040 | Pending |
| Jurisdiction | Patent/Application No. | Filing Date | Grant Date | Expiration Date | Status |
| United States* | 18/189,012 | October 20, 2023 | — | April 22, 2040 | Pending |
| People's Republic of China | CN 202380034567.1 | October 18, 2023 | — | April 22, 2040 | Pending |
| Japan | JP 2024-545678 | October 20, 2023 | — | April 22, 2040 | Pending |
| Republic of Korea | KR 10-2024-7025678 | October 18, 2023 | — | April 22, 2040 | Pending |
| Australia | AU 2023245678 | October 20, 2023 | — | April 22, 2040 | Pending |
| New Zealand | NZ 845678 | October 20, 2023 | — | April 22, 2040 | Pending |
| Singapore | SG 11202309012B | October 18, 2023 | — | April 22, 2040 | Pending |
| Thailand | TH 2301008901 | October 20, 2023 | — | April 22, 2040 | Pending |
| Malaysia | MY PI2023007890 | October 20, 2023 | — | April 22, 2040 | Pending |
| Indonesia | ID P00202308901 | October 20, 2023 | — | April 22, 2040 | Pending |
| Philippines | PH 1-2023-552345 | October 18, 2023 | — | April 22, 2040 | Pending |
| Vietnam | VN 1-2023-07890 | October 20, 2023 | — | April 22, 2040 | Pending |
| Taiwan | TW 112138901 | October 18, 2023 | — | April 22, 2040 | Pending |
| Family No. | Family Description | Jurisdiction | Patent/Application No. | Filing Date | Grant Date | Expiration Date | Status | Assignee |
| 1 | Composition of Matter | United States* | 11,234,567 | Jul. 15, 2019 | Jan. 25, 2022 | Aug. 12, 2037 | Granted | Penterra |
| 1 | Composition of Matter | China | ZL 2020 1 0456789.0 | Jan. 14, 2020 | Sep. 8, 2023 | Aug. 12, 2037 | Granted | Penterra |
| 1 | Composition of Matter | Japan | 7,012,345 | Jan. 15, 2020 | Jun. 23, 2023 | Aug. 12, 2037 | Granted | Penterra |
| 1 | Composition of Matter | Republic of Korea | 10-2345678 | Jan. 14, 2020 | Aug. 4, 2023 | Aug. 12, 2037 | Granted | Penterra |
| 1 | Composition of Matter | Australia | 2020234567 | Jan. 15, 2020 | Mar. 17, 2023 | Aug. 12, 2037 | Granted | Penterra |
| 1 | Composition of Matter | New Zealand | 773456 | Jan. 15, 2020 | Jul. 28, 2023 | Aug. 12, 2037 | Granted | Penterra |
| 1 | Composition of Matter | Singapore | 11202000456T | Jan. 14, 2020 | — | Aug. 12, 2037 | Pending | Penterra |
| 1 | Composition of Matter | Thailand | 2001000345 | Jan. 15, 2020 | — | Aug. 12, 2037 | Pending | Penterra |
| 1 | Composition of Matter | Malaysia | PI2020000789 | Jan. 15, 2020 | — | Aug. 12, 2037 | Pending | Penterra |
| 1 | Composition of Matter | Indonesia | P00202000567 | Jan. 15, 2020 | — | Aug. 12, 2037 | Pending | Penterra |
| 1 | Composition of Matter | Philippines | 1-2020-500123 | Jan. 14, 2020 | — | Aug. 12, 2037 | Pending | Penterra |
| 1 | Composition of Matter | Vietnam | 1-2020-00234 | Jan. 15, 2020 | — | Aug. 12, 2037 | Pending | Penterra |
| 1 | Composition of Matter | Taiwan | 109101234 | Jan. 14, 2020 | — | Aug. 12, 2037 | Pending | Penterra |
| 2 | Crystalline Forms | United States* | 11,345,678 | Nov. 3, 2020 | May 16, 2023 | Nov. 3, 2038 | Granted | Penterra |
| 2 | Crystalline Forms | China | CN 202180012345.6 | May 2, 2022 | — | Nov. 3, 2038 | Pending | Penterra |
| 2 | Crystalline Forms | Japan | JP 2022-527891 | May 3, 2022 | — | Nov. 3, 2038 | Pending | Penterra |
| 2 | Crystalline Forms | Republic of Korea | KR 10-2022-7013456 | May 2, 2022 | — | Nov. 3, 2038 | Pending | Penterra |
| 2 | Crystalline Forms | Australia | AU 2021367890 | May 3, 2022 | — | Nov. 3, 2038 | Pending | Penterra |
| 2 | Crystalline Forms | New Zealand | NZ 789012 | May 3, 2022 | — | Nov. 3, 2038 | Pending | Penterra |
| 2 | Crystalline Forms | Singapore | SG 11202204567X | May 2, 2022 | — | Nov. 3, 2038 | Pending | Penterra |
| 2 | Crystalline Forms | Thailand | TH 2201001234 | May 3, 2022 | — | Nov. 3, 2038 | Pending | Penterra |
| 2 | Crystalline Forms | Malaysia | MY PI2022002345 | May 3, 2022 | — | Nov. 3, 2038 | Pending | Penterra |
| 2 | Crystalline Forms | Indonesia | ID P00202203456 | May 3, 2022 | — | Nov. 3, 2038 | Pending | Penterra |
| 2 | Crystalline Forms | Philippines | PH 1-2022-550234 | May 2, 2022 | — | Nov. 3, 2038 | Pending | Penterra |
| 2 | Crystalline Forms | Vietnam | VN 1-2022-02345 | May 3, 2022 | — | Nov. 3, 2038 | Pending | Penterra |
| 2 | Crystalline Forms | Taiwan | TW 111116789 | May 2, 2022 | — | Nov. 3, 2038 | Pending | Penterra |
| 3 | Methods of Use | United States* | 17/456,789 | Nov. 28, 2022 | — | May 28, 2039 | Pending | Penterra |
| 3 | Methods of Use | China | CN 202280023456.7 | Nov. 25, 2022 | — | May 28, 2039 | Pending | Penterra |
| 3 | Methods of Use | Japan | JP 2023-572345 | Nov. 28, 2022 | — | May 28, 2039 | Pending | Penterra |
| 3 | Methods of Use | Republic of Korea | KR 10-2023-7030123 | Nov. 25, 2022 | — | May 28, 2039 | Pending | Penterra |
| 3 | Methods of Use | Australia | AU 2022278901 | Nov. 28, 2022 | — | May 28, 2039 | Pending | Penterra |
| 3 | Methods of Use | New Zealand | NZ 801234 | Nov. 28, 2022 | — | May 28, 2039 | Pending | Penterra |
| 3 | Methods of Use | Singapore | SG 11202212345A | Nov. 25, 2022 | — | May 28, 2039 | Pending | Penterra |
| 3 | Methods of Use | Thailand | TH 2201003456 | Nov. 28, 2022 | — | May 28, 2039 | Pending | Penterra |
| 3 | Methods of Use | Malaysia | MY PI2022006789 | Nov. 28, 2022 | — | May 28, 2039 | Pending | Penterra |
| 3 | Methods of Use | Indonesia | ID P00202209012 | Nov. 28, 2022 | — | May 28, 2039 | Pending | Penterra |
| 3 | Methods of Use | Philippines | PH 1-2022-551234 | Nov. 25, 2022 | — | May 28, 2039 | Pending | Penterra |
| 3 | Methods of Use | Vietnam | VN 1-2022-05678 | Nov. 28, 2022 | — | May 28, 2039 | Pending | Penterra |
| 3 | Methods of Use | Taiwan | TW 111143210 | Nov. 25, 2022 | — | May 28, 2039 | Pending | Penterra |
| 4 | Pharmaceutical Formulations | United States* | 17/512,345 | Jan. 10, 2023 | — | Jul. 12, 2039 | Pending | Penterra |
| 4 | Pharmaceutical Formulations | China | CN 202280034567.8 | Jan. 8, 2023 | — | Jul. 12, 2039 | Pending | Penterra |
| 4 | Pharmaceutical Formulations | Japan | JP 2024-501234 | Jan. 10, 2023 | — | Jul. 12, 2039 | Pending | Penterra |
| 4 | Pharmaceutical Formulations | Republic of Korea | KR 10-2024-7001234 | Jan. 8, 2023 | — | Jul. 12, 2039 | Pending | Penterra |
| 4 | Pharmaceutical Formulations | Australia | AU 2022312345 | Jan. 10, 2023 | — | Jul. 12, 2039 | Pending | Penterra |
| 4 | Pharmaceutical Formulations | New Zealand | NZ 812345 | Jan. 10, 2023 | — | Jul. 12, 2039 | Pending | Penterra |
| 4 | Pharmaceutical Formulations | Singapore | SG 11202300123W | Jan. 8, 2023 | — | Jul. 12, 2039 | Pending | Penterra |
| 4 | Pharmaceutical Formulations | Thailand | TH 2301000567 | Jan. 10, 2023 | — | Jul. 12, 2039 | Pending | Penterra |
| 4 | Pharmaceutical Formulations | Malaysia | MY PI2023000234 | Jan. 10, 2023 | — | Jul. 12, 2039 | Pending | Penterra |
| 4 | Pharmaceutical Formulations | Indonesia | ID P00202300456 | Jan. 10, 2023 | — | Jul. 12, 2039 | Pending | Penterra |
| 4 | Pharmaceutical Formulations | Philippines | PH 1-2023-550012 | Jan. 8, 2023 | — | Jul. 12, 2039 | Pending | Penterra |
| 4 | Pharmaceutical Formulations | Vietnam | VN 1-2023-00123 | Jan. 10, 2023 | — | Jul. 12, 2039 | Pending | Penterra |
| 4 | Pharmaceutical Formulations | Taiwan | TW 112100345 | Jan. 8, 2023 | — | Jul. 12, 2039 | Pending | Penterra |
| 5 | Manufacturing Process | United States* | 17/534,567 | Mar. 3, 2023 | — | Sep. 3, 2039 | Pending | Penterra |
| 5 | Manufacturing Process | China | CN 202280045678.9 | Mar. 1, 2023 | — | Sep. 3, 2039 | Pending | Penterra |
| 5 | Manufacturing Process | Japan | JP 2024-512345 | Mar. 3, 2023 | — | Sep. 3, 2039 | Pending | Penterra |
| 5 | Manufacturing Process | Republic of Korea | KR 10-2024-7008901 | Mar. 1, 2023 | — | Sep. 3, 2039 | Pending | Penterra |
| 5 | Manufacturing Process | Australia | AU 2022345678 | Mar. 3, 2023 | — | Sep. 3, 2039 | Pending | Penterra |
| 5 | Manufacturing Process | New Zealand | NZ 823456 | Mar. 3, 2023 | — | Sep. 3, 2039 | Pending | Penterra |
| 5 | Manufacturing Process | Singapore | SG 11202301234Y | Mar. 1, 2023 | — | Sep. 3, 2039 | Pending | Penterra |
| 5 | Manufacturing Process | Thailand | TH 2301002345 | Mar. 3, 2023 | — | Sep. 3, 2039 | Pending | Penterra |
| 5 | Manufacturing Process | Malaysia | MY PI2023001567 | Mar. 3, 2023 | — | Sep. 3, 2039 | Pending | Penterra |
| 5 | Manufacturing Process | Indonesia | ID P00202301890 | Mar. 3, 2023 | — | Sep. 3, 2039 | Pending | Penterra |
| 5 | Manufacturing Process | Philippines | PH 1-2023-550345 | Mar. 1, 2023 | — | Sep. 3, 2039 | Pending | Penterra |
| 5 | Manufacturing Process | Vietnam | VN 1-2023-01456 | Mar. 3, 2023 | — | Sep. 3, 2039 | Pending | Penterra |
| 5 | Manufacturing Process | Taiwan | TW 112107890 | Mar. 1, 2023 | — | Sep. 3, 2039 | Pending | Penterra |
| 6 | Combination Therapy | United States* | 18/156,789 | Jul. 12, 2023 | — | Jan. 14, 2040 | Pending | Penterra |
| 6 | Combination Therapy | China | CN 202380012345.0 | Jul. 10, 2023 | — | Jan. 14, 2040 | Pending | Penterra |
| 6 | Combination Therapy | Japan | JP 2024-534567 | Jul. 12, 2023 | — | Jan. 14, 2040 | Pending | Penterra |
| 6 | Combination Therapy | Republic of Korea | KR 10-2024-7018901 | Jul. 10, 2023 | — | Jan. 14, 2040 | Pending | Penterra |
| 6 | Combination Therapy | Australia | AU 2023201234 | Jul. 12, 2023 | — | Jan. 14, 2040 | Pending | Penterra |
| 6 | Combination Therapy | New Zealand | NZ 834567 | Jul. 12, 2023 | — | Jan. 14, 2040 | Pending | Penterra |
| 6 | Combination Therapy | Singapore | SG 11202306789Z | Jul. 10, 2023 | — | Jan. 14, 2040 | Pending | Penterra |
| 6 | Combination Therapy | Thailand | TH 2301005678 | Jul. 12, 2023 | — | Jan. 14, 2040 | Pending | Penterra |
| 6 | Combination Therapy | Malaysia | MY PI2023004567 | Jul. 12, 2023 | — | Jan. 14, 2040 | Pending | Penterra |
| 6 | Combination Therapy | Indonesia | ID P00202305678 | Jul. 12, 2023 | — | Jan. 14, 2040 | Pending | Penterra |
| 6 | Combination Therapy | Philippines | PH 1-2023-551234 | Jul. 10, 2023 | — | Jan. 14, 2040 | Pending | Penterra |
| 6 | Combination Therapy | Vietnam | VN 1-2023-04567 | Jul. 12, 2023 | — | Jan. 14, 2040 | Pending | Penterra |
| 6 | Combination Therapy | Taiwan | TW 112125678 | Jul. 10, 2023 | — | Jan. 14, 2040 | Pending | Penterra |
| 7 | Dosage Regimen | United States* | 18/189,012 | Oct. 20, 2023 | — | Apr. 22, 2040 | Pending | Penterra |
| 7 | Dosage Regimen | China | CN 202380034567.1 | Oct. 18, 2023 | — | Apr. 22, 2040 | Pending | Penterra |
| 7 | Dosage Regimen | Japan | JP 2024-545678 | Oct. 20, 2023 | — | Apr. 22, 2040 | Pending | Penterra |
| 7 | Dosage Regimen | Republic of Korea | KR 10-2024-7025678 | Oct. 18, 2023 | — | Apr. 22, 2040 | Pending | Penterra |
| 7 | Dosage Regimen | Australia | AU 2023245678 | Oct. 20, 2023 | — | Apr. 22, 2040 | Pending | Penterra |
| 7 | Dosage Regimen | New Zealand | NZ 845678 | Oct. 20, 2023 | — | Apr. 22, 2040 | Pending | Penterra |
| 7 | Dosage Regimen | Singapore | SG 11202309012B | Oct. 18, 2023 | — | Apr. 22, 2040 | Pending | Penterra |
| 7 | Dosage Regimen | Thailand | TH 2301008901 | Oct. 20, 2023 | — | Apr. 22, 2040 | Pending | Penterra |
| 7 | Dosage Regimen | Malaysia | MY PI2023007890 | Oct. 20, 2023 | — | Apr. 22, 2040 | Pending | Penterra |
| 7 | Dosage Regimen | Indonesia | ID P00202308901 | Oct. 20, 2023 | — | Apr. 22, 2040 | Pending | Penterra |
| 7 | Dosage Regimen | Philippines | PH 1-2023-552345 | Oct. 18, 2023 | — | Apr. 22, 2040 | Pending | Penterra |
| 7 | Dosage Regimen | Vietnam | VN 1-2023-07890 | Oct. 20, 2023 | — | Apr. 22, 2040 | Pending | Penterra |
| 7 | Dosage Regimen | Taiwan | TW 112138901 | Oct. 18, 2023 | — | Apr. 22, 2040 | Pending | Penterra |
| PCT Application No. | International Filing Date | Patent Family | Applicant | Status |
| PCT/US2019/045123 | July 15, 2019 | Family 1 — Composition of Matter | Penterra Pharmaceuticals Corp. | National phase entries completed; PCT application no longer pending |
| PCT/US2020/058901 | November 3, 2020 | Family 2 — Crystalline Forms | Penterra Pharmaceuticals Corp. | National phase entries completed; PCT application no longer pending |
| PCT/US2021/034567 | May 28, 2021 | Family 3 — Methods of Use | Penterra Pharmaceuticals Corp. | National phase entries completed; PCT application no longer pending |
| PCT/US2021/041234 | July 12, 2021 | Family 4 — Pharmaceutical Formulations | Penterra Pharmaceuticals Corp. | National phase entries completed; PCT application no longer pending |
| PCT/US2021/048901 | September 3, 2021 | Family 5 — Manufacturing Process | Penterra Pharmaceuticals Corp. | National phase entries completed; PCT application no longer pending |
| PCT/US2022/012345 | January 14, 2022 | Family 6 — Combination Therapy | Penterra Pharmaceuticals Corp. | National phase entries completed; PCT application no longer pending |
| PCT/US2022/025678 | April 22, 2022 | Family 7 — Dosage Regimen | Penterra Pharmaceuticals Corp. | National phase entries completed; PCT application no longer pending |
SCHEDULE A — LICENSED PATENTS
Schedule A to the Exclusive License Agreement dated October 2, 2023 (effective October 20, 2023)
between
Penterra Pharmaceuticals Corp. a Delaware corporation ("Licensor")
and
Meridian Bio Therapeutics Limited a Hong Kong limited company ("Licensee")
Compound: PPC-4187 (Penteracitinib)
This Schedule A is attached to and incorporated by reference into the Exclusive License Agreement (the "Agreement") between Penterra Pharmaceuticals Corp., a Delaware corporation ("Licensor"), and Meridian Bio Therapeutics Limited, a Hong Kong limited company ("Licensee"), dated October 2, 2023, with an Effective Date of October 20, 2023. Capitalized terms not otherwise defined herein shall have the meanings ascribed to them in the Agreement.
Patent prosecution counsel for the Licensed Patents identified herein is Whitford & Cascade Insurance Brokers (Dr. Alan J. Whitford, Lead Patent Attorney), 1750 K Street NW, Suite 600, Washington, DC 20006. All references to prosecution coordination herein are to the activities of such counsel, unless otherwise stated.
Section 1: Overview of Licensed Patent Portfolio
The Licensed Patents licensed to Licensee under the Agreement consist of seven (7) patent families covering the following subject matter areas relating to the compound designated PPC-4187 (Penteracitinib):
The Licensed Patents include all patents and patent applications listed below in Sections 2 through 8 of this Schedule A, together with all continuations, continuations-in-part, divisionals, reissues, reexaminations, patent term extensions, supplementary protection certificates, and any foreign counterparts thereof in the Territory. The Licensed Patents further include any patents or patent applications that claim priority to, or share a common priority date with, the patents and patent applications listed herein, to the extent such patents or patent applications are filed in or cover a jurisdiction within the Territory.
The Territory is defined in Schedule D to the Agreement and comprises the following jurisdictions: the People's Republic of China (including Hong Kong Special Administrative Region and Macau Special Administrative Region), Japan, the Republic of Korea, Australia, New Zealand, Singapore, Thailand, Malaysia, Indonesia, the Philippines, Vietnam, and Taiwan.
For each Patent Family, patents and patent applications in the United States are listed for completeness and cross-reference purposes only. United States patents are retained by Licensor for use in the Retained Territory and are not licensed to Licensee for exploitation in the United States; however, such United States patents are included in this Schedule A solely for the purposes of the cross-license-back and patent coordination provisions of Article 12 of the Agreement.
Section 2: Patent Family 1 — Composition of Matter
Description: Patent Family 1 covers the novel chemical compound PPC-4187 (Penteracitinib), a selective Janus kinase 1 (JAK1) inhibitor, including its free base, pharmaceutically acceptable salts (including, without limitation, hydrochloride, mesylate, tosylate, fumarate, and tartrate salts), solvates, hydrates, polymorphs, and prodrugs thereof. This patent family provides the foundational intellectual property protection for the PPC-4187 compound and is the primary composition-of-matter patent family in the Licensed Patent portfolio.
PCT Application: PCT/US2019/045123, International Filing Date: July 15, 2019, Applicant: Penterra Pharmaceuticals Corp. National phase entries have been completed in each of the jurisdictions listed below.
2.1 United States
Note: This United States patent is a Retained Territory patent. It is included in this Schedule A solely for purposes of the cross-license-back and patent coordination provisions of Article 12 of the Agreement. U.S. Patent No. 11,234,567 is not licensed to Licensee for use in the United States or any jurisdiction outside the Territory, but is listed for completeness and cross-reference.
2.2 People's Republic of China
Prosecution of this patent was handled by Whitford & Cascade Insurance Brokers in coordination with local PRC patent agent, Zhonghui Patent & Trademark Agency (Beijing). The granted claims include twenty-three (23) claims covering the compound PPC-4187 in free base form and as pharmaceutically acceptable salts thereof.
2.3 Japan.
2.4 Republic of Korea
2.5 Australia.
2.6 New Zealand
2.7 Singapore.
2.8 Thailand.
2.9 Malaysia.
2.10 Indonesia.
2.11 Philippines.
2.12 Vietnam.
2.13 Taiwan.
Section 3: Patent Family 2 — Crystalline Forms
Description: Patent Family 2 covers Crystalline Form A of PPC-4187 (Penteracitinib), including its characterization by X-ray powder diffraction (XRPD) pattern, differential scanning calorimetry (DSC), thermogravimetric analysis (TGA), and other solid-state characterization data. The claims in this patent family cover Crystalline Form A as characterized by specific 2-theta values in the XRPD pattern, processes for preparing Crystalline Form A, and pharmaceutical compositions comprising Crystalline Form A.
3.1 United States
Note: This United States patent is a Retained Territory patent. It is listed in this Schedule A for completeness and cross-reference purposes only, per the provisions of Article 12 of the Agreement.
3.2 Territory National Phase Entries
National phase entries from the corresponding PCT application (PCT/US2020/058901, International Filing Date: November 3, 2020) have been filed in each of the Territory jurisdictions listed below. As of the Effective Date, all Territory national phase applications for Patent Family 2 remain pending unless otherwise noted.
All applications listed above are assigned to Penterra Pharmaceuticals Corp. Prosecution in each Territory jurisdiction is coordinated by Whitford & Cascade Insurance Brokers (Dr. Alan J. Whitford) in consultation with local patent agents and counsel in each respective jurisdiction.
Section 4: Patent Family 3 — Methods of Use
Description: Patent Family 3 covers methods of treating moderate-to-severe atopic dermatitis in adult patients using PPC-4187 (Penteracitinib), including dosage-specific method claims for 25 mg and 50 mg once-daily oral administration. The claims in this patent family are supported by clinical data from Study PPC-4187-201, a multi-center, randomized, double-blind, placebo-controlled Phase IIb clinical trial enrolling 420 patients, which demonstrated an EASI-75 response at Week 16 with statistical significance (p<0.001 vs. placebo). Study PPC-4187-201 was completed in June 2023.
The corresponding PCT application for this family is PCT/US2021/034567, with an International Filing Date of May 28, 2021. National phase entries have been completed in the United States and in each Territory jurisdiction as set forth below.
4.1 Jurisdiction Table
*United States application listed for cross-reference and patent coordination purposes only pursuant to Article 12 of the Agreement. Not licensed to Licensee for use in the United States.
All applications listed above are assigned to Penterra Pharmaceuticals Corp. All expiration dates stated above are expected expiration dates, assuming grant, and are calculated before any patent term extension, patent term adjustment, supplementary protection certificate, or equivalent extension.
Section 5: Patent Family 4 — Pharmaceutical Formulations
Description: Patent Family 4 covers oral pharmaceutical compositions comprising PPC-4187 (Penteracitinib), including film-coated tablet formulations at 25 mg and 50 mg dosage strengths, and specific excipient combinations including microcrystalline cellulose, lactose monohydrate, croscarmellose sodium, magnesium stearate, and an Thackeray Systems® II film coating system. Claims in this patent family encompass the finished dosage form, methods of preparing the dosage form, and the combination of excipients with PPC-4187 in specified proportions.
The corresponding PCT application for this family is PCT/US2021/041234, with an International Filing Date of July 12, 2021. National phase entries have been completed in the United States and in each Territory jurisdiction as set forth below.
5.1 Jurisdiction Table
*United States application listed for cross-reference and patent coordination purposes only pursuant to Article 12 of the Agreement. Not licensed to Licensee for use in the United States.
All applications listed above are assigned to Penterra Pharmaceuticals Corp. All expiration dates stated above are expected expiration dates, assuming grant, and are calculated before any patent term extension, patent term adjustment, supplementary protection certificate, or equivalent extension.
Section 6: Patent Family 5 — Manufacturing Process
Description: Patent Family 5 covers proprietary manufacturing processes for the synthesis and purification of PPC-4187 (Penteracitinib) active pharmaceutical ingredient (API), including key synthetic intermediates, catalytic coupling reactions, crystallization conditions, and critical process parameters for commercial-scale manufacturing. The manufacturing process described in this patent family has been validated at Alkerra Manufacturing Inc., 5200 Meridian Parkway, Research Triangle Park, NC 27713, pursuant to current Good Manufacturing Practice (cGMP) requirements.
The corresponding PCT application for this family is PCT/US2021/048901, with an International Filing Date of September 3, 2021. National phase entries have been completed in the United States and in each Territory jurisdiction as set forth below.
6.1 Jurisdiction Table
*United States application listed for cross-reference and patent coordination purposes only pursuant to Article 12 of the Agreement. Not licensed to Licensee for use in the United States.
All applications listed above are assigned to Penterra Pharmaceuticals Corp. All expiration dates stated above are expected expiration dates, assuming grant, and are calculated before any patent term extension, patent term adjustment, supplementary protection certificate, or equivalent extension.
Section 7: Patent Family 6 — Combination Therapy
Description: Patent Family 6 covers methods and compositions for administering PPC-4187 (Penteracitinib) in combination with other therapeutic agents for the treatment of atopic dermatitis and related inflammatory conditions. Specifically, the claims encompass the co-administration of PPC-4187 with one or more topical corticosteroids, topical calcineurin inhibitors, phosphodiesterase-4 (PDE4) inhibitors, or biologic agents targeting interleukin-4 (IL-4), interleukin-13 (IL-13), or interleukin-31 (IL-31) pathways, in patients with moderate-to-severe atopic dermatitis.
The corresponding PCT application for this family is PCT/US2022/012345, with an International Filing Date of January 14, 2022. National phase entries have been completed in the United States and in each Territory jurisdiction as set forth below.
7.1 Jurisdiction Table
*United States application listed for cross-reference and patent coordination purposes only pursuant to Article 12 of the Agreement. Not licensed to Licensee for use in the United States.
All applications listed above are assigned to Penterra Pharmaceuticals Corp. All expiration dates stated above are expected expiration dates, assuming grant, and are calculated before any patent term extension, patent term adjustment, supplementary protection certificate, or equivalent extension.
Section 8: Patent Family 7 — Dosage Regimen
Description: Patent Family 7 covers specific dosage regimens for once-daily oral administration of PPC-4187 (Penteracitinib) at specified dose levels for the treatment of moderate-to-severe atopic dermatitis, including titration protocols (e.g., initiation at 25 mg once daily for two weeks followed by escalation to 50 mg once daily), patient selection criteria based on baseline disease severity (Eczema Area and Severity Index score ≥16 and Investigator's Global Assessment score ≥3), and dose adjustment criteria for patients with hepatic or renal impairment.
The corresponding PCT application for this family is PCT/US2022/025678, with an International Filing Date of April 22, 2022. National phase entries have been completed in the United States and in each Territory jurisdiction as set forth below.
8.1 Jurisdiction Table
*United States application listed for cross-reference and patent coordination purposes only pursuant to Article 12 of the Agreement. Not licensed to Licensee for use in the United States.
All applications listed above are assigned to Penterra Pharmaceuticals Corp. All expiration dates stated above are expected expiration dates, assuming grant, and are calculated before any patent term extension, patent term adjustment, supplementary protection certificate, or equivalent extension.
Section 9: Summary Table — All Licensed Patents
The following consolidated summary table lists all patents and patent applications across all seven (7) patent families and all jurisdictions. Entries marked with an asterisk (*) under the "Jurisdiction" column denote United States patents and applications that are listed for cross-reference and patent coordination purposes only pursuant to Article 12 of the Agreement and are not licensed to Licensee for exploitation in the United States.
The total portfolio as of the Effective Date comprises seven (7) patent families filed across up to thirteen (13) jurisdictions (the United States plus twelve (12) Territory jurisdictions), for a maximum of ninety-one (91) entries. As of the Effective Date, certain patent families have not yet been filed in all Territory jurisdictions; the table below reflects the actual filings as of October 20, 2023.
Entries marked with an asterisk () are United States patents or patent applications retained by Licensor for the Retained Territory and are listed solely for cross-reference and patent coordination purposes under Article 12 of the Agreement. "Penterra" refers to Penterra Pharmaceuticals Corp. All expiration dates are stated before any applicable patent term extension, patent term adjustment, supplementary protection certificate, or equivalent extension.
Section 10: PCT Applications
The following PCT applications serve as the basis for the national phase entries in the Licensed Patent portfolio:
In each case, national phase entries from the respective PCT applications have been filed in the United States and in each of the Territory jurisdictions identified in Sections 2 through 8 above and in the Summary Table in Section 9 above. The PCT applications themselves are no longer pending, having served their purpose as the basis for national and regional phase entries.
Section 11: Notes and Qualifications
11.1 Expiration Dates. All expiration dates set forth in this Schedule A are stated before any patent term extension ("PTE"), patent term adjustment ("PTA"), supplementary protection certificate ("SPC"), or equivalent extension that may be available under the applicable laws of the relevant jurisdiction. To the extent that any PTE, PTA, SPC, or equivalent extension is obtained for any Licensed Patent, the expiration date of such Licensed Patent shall be deemed extended accordingly for all purposes under the Agreement, and this Schedule A shall be updated to reflect such extension in accordance with Section 11.5 below.
11.2 Pending Applications. Pending patent applications listed in this Schedule A are subject to examination by the relevant patent office in each jurisdiction and may not result in granted patents. The scope of any claims that may ultimately be granted may differ from the claims as filed. Licensor makes no warranty or representation that any pending application will be granted or that the claims of any pending application will be granted in the form currently pending. The representations and warranties of Licensor regarding the Licensed Patents, including with respect to validity, enforceability, ownership, and freedom from encumbrances, are set forth exclusively in Article 9 of the Agreement, and nothing in this Schedule A shall be construed to expand or modify such representations and warranties.
11.3 Joint Patent Committee. The Joint Patent Committee ("JPC"), comprised of two (2) representatives designated by Licensor and two (2) representatives designated by Licensee, shall oversee the prosecution, maintenance, defense, and enforcement of the Licensed Patents in the Territory, as more fully set forth in Article 12 of the Agreement. The JPC shall meet not less frequently than quarterly and shall coordinate all material prosecution and enforcement decisions relating to the Licensed Patents in the Territory, including the filing of responses to office actions, the initiation or defense of opposition, invalidation, or revocation proceedings, and the pursuit of any patent term extensions or supplementary protection certificates.
11.4 Patent Prosecution Coordination. Patent prosecution for the Licensed Patents in the Territory is coordinated by Whitford & Cascade Insurance Brokers (Dr. Alan J. Whitford, Lead Patent Attorney), in consultation with local counsel and patent agents in each Territory jurisdiction. The selection and retention of local counsel and patent agents in each jurisdiction shall be subject to the mutual agreement of the parties through the JPC, as provided in Article 12 of the Agreement. Licensor shall bear all costs and expenses of prosecution and maintenance of the Licensed Patents in the United States; Licensee shall bear all costs and expenses of prosecution and maintenance of the Licensed Patents in the Territory, in each case as more fully described in Section 12.4 of the Agreement.
11.5 Updates to Schedule A. This Schedule A shall be updated from time to time by mutual written agreement of the parties to reflect (a) newly granted patents (including the grant date, patent number, and scope of granted claims), (b) newly filed patent applications (including continuations, continuations-in-part, divisionals, and new national phase entries), (c) any changes in the status of any Listed Patent or patent application (including abandonment, withdrawal, lapse, revocation, invalidation, or expiration), (d) any patent term extensions, patent term adjustments, supplementary protection certificates, or equivalent extensions obtained, and (e) any assignments or changes in ownership. Updates to this Schedule A shall be made in accordance with Section 14.8 of the Agreement and shall not require a formal amendment to the Agreement, provided that both parties have consented in writing to the updated Schedule A.
11.6 Royalty Term. The royalty term under the Agreement is, on a country-by-country and product-by-product basis, the period commencing on the date of first commercial sale of a Licensed Product in such country and ending on the later of (a) the expiration of the last-to-expire Valid Claim of a Licensed Patent covering such Licensed Product in such country, or (b) twelve (12) years from the date of first commercial sale of such Licensed Product in such country, as more fully described in Section 7.3 of the Agreement. Following expiration of the royalty term in a given country, the license granted to Licensee under the Agreement with respect to such country shall become a fully paid-up, irrevocable, perpetual, non-exclusive license, as set forth in Section 7.4 of the Agreement.
— End of Schedule A —
Cross-References:
This Schedule A should be read in conjunction with the following additional Schedules to the Agreement:
• Schedule B — Licensed Know-How
• Schedule C — Licensed Trademarks
• Schedule D — Territory
Each of the foregoing Schedules is attached to and incorporated by reference into the Agreement between Penterra Pharmaceuticals Corp. and Meridian Bio Therapeutics Limited, dated October 2, 2023 (Effective Date: October 20, 2023).
As of the Effective Date: October 20, 2023. This Schedule A is confidential and subject to the confidentiality provisions set forth in Article 13 of the Agreement.
Patent Family No. | Subject Matter
Family 1 | Composition of Matter
Family 2 | Crystalline Forms (Form A)
Family 3 | Methods of Use (Treatment of Atopic Dermatitis)
Family 4 | Pharmaceutical Formulations
Family 5 | Manufacturing Process
Family 6 | Combination Therapy
Family 7 | Dosage Regimen
Field | Detail
Patent No. | 11,234,567
Title | Selective JAK1 Inhibitor Compounds and Pharmaceutically Acceptable Salts Thereof
Filing Date | July 15, 2019 (national phase entry from PCT/US2019/045123)
Grant Date | January 25, 2022
Expiration Date | August 12, 2037 (before any patent term extension or patent term adjustment)
Status | Granted
Assignee | Penterra Pharmaceuticals Corp.
Field | Detail
Patent No. | ZL 2020 1 0456789.0
Title | Selective JAK1 Inhibitor Compounds and Pharmaceutically Acceptable Salts Thereof
Filing Date | January 14, 2020 (national phase entry from PCT/US2019/045123)
Grant Date | September 8, 2023
Expiration Date | August 12, 2037
Status | Granted
Assignee | Penterra Pharmaceuticals Corp.
Field | Detail
Patent No. | 7,012,345
Title | Selective JAK1 Inhibitor Compounds and Pharmaceutically Acceptable Salts Thereof
Filing Date | January 15, 2020 (national phase entry from PCT/US2019/045123)
Grant Date | June 23, 2023
Expiration Date | August 12, 2037
Status | Granted
Assignee | Penterra Pharmaceuticals Corp.
Field | Detail
Patent No. | 10-2345678
Title | Selective JAK1 Inhibitor Compounds and Pharmaceutically Acceptable Salts Thereof
Filing Date | January 14, 2020 (national phase entry from PCT/US2019/045123)
Grant Date | August 4, 2023
Expiration Date | August 12, 2037
Status | Granted
Assignee | Penterra Pharmaceuticals Corp.
Field | Detail
Patent No. | 2020234567
Title | Selective JAK1 Inhibitor Compounds and Pharmaceutically Acceptable Salts Thereof
Filing Date | January 15, 2020 (national phase entry from PCT/US2019/045123)
Grant Date | March 17, 2023
Expiration Date | August 12, 2037
Status | Granted
Assignee | Penterra Pharmaceuticals Corp.
Field | Detail
Application No. | 773456
Title | Selective JAK1 Inhibitor Compounds and Pharmaceutically Acceptable Salts Thereof
Filing Date | January 15, 2020 (national phase entry from PCT/US2019/045123)
Grant Date | July 28, 2023
Expiration Date | August 12, 2037
Status | Granted
Assignee | Penterra Pharmaceuticals Corp.
Field | Detail
Application No. | 11202000456T
Title | Selective JAK1 Inhibitor Compounds and Pharmaceutically Acceptable Salts Thereof
Filing Date | January 14, 2020 (national phase entry from PCT/US2019/045123)
Expected Expiration Date | August 12, 2037 (if granted)
Status | Pending
Assignee | Penterra Pharmaceuticals Corp.
Field | Detail
Application No. | 2001000345
Title | Selective JAK1 Inhibitor Compounds and Pharmaceutically Acceptable Salts Thereof
Filing Date | January 15, 2020 (national phase entry from PCT/US2019/045123)
Expected Expiration Date | August 12, 2037 (if granted)
Status | Pending
Assignee | Penterra Pharmaceuticals Corp.
Field | Detail
Application No. | PI2020000789
Title | Selective JAK1 Inhibitor Compounds and Pharmaceutically Acceptable Salts Thereof
Filing Date | January 15, 2020 (national phase entry from PCT/US2019/045123)
Expected Expiration Date | August 12, 2037 (if granted)
Status | Pending
Assignee | Penterra Pharmaceuticals Corp.
Field | Detail
Application No. | P00202000567
Title | Selective JAK1 Inhibitor Compounds and Pharmaceutically Acceptable Salts Thereof
Filing Date | January 15, 2020 (national phase entry from PCT/US2019/045123)
Expected Expiration Date | August 12, 2037 (if granted)
Status | Pending
Assignee | Penterra Pharmaceuticals Corp.
Field | Detail
Application No. | 1-2020-500123
Title | Selective JAK1 Inhibitor Compounds and Pharmaceutically Acceptable Salts Thereof
Filing Date | January 14, 2020 (national phase entry from PCT/US2019/045123)
Expected Expiration Date | August 12, 2037 (if granted)
Status | Pending
Assignee | Penterra Pharmaceuticals Corp.
Field | Detail
Application No. | 1-2020-00234
Title | Selective JAK1 Inhibitor Compounds and Pharmaceutically Acceptable Salts Thereof
Filing Date | January 15, 2020 (national phase entry from PCT/US2019/045123)
Expected Expiration Date | August 12, 2037 (if granted)
Status | Pending
Assignee | Penterra Pharmaceuticals Corp.
Field | Detail
Application No. | 109101234
Title | Selective JAK1 Inhibitor Compounds and Pharmaceutically Acceptable Salts Thereof
Filing Date | January 14, 2020 (national phase entry from PCT/US2019/045123)
Expected Expiration Date | August 12, 2037 (if granted)
Status | Pending
Assignee | Penterra Pharmaceuticals Corp.
Field | Detail
Patent No. | 11,345,678
Title | Crystalline Forms of a Selective JAK1 Inhibitor
Filing Date | November 3, 2020
Grant Date | May 16, 2023
Expiration Date | November 3, 2038 (before any patent term extension or patent term adjustment)
Status | Granted
Assignee | Penterra Pharmaceuticals Corp.
Jurisdiction | Application No. | Filing Date | Grant Date | Expected Expiration | Status
People's Republic of China | CN 202180012345.6 | May 2, 2022 | — | November 3, 2038 | Pending
Japan | JP 2022-527891 | May 3, 2022 | — | November 3, 2038 | Pending
Republic of Korea | KR 10-2022-7013456 | May 2, 2022 | — | November 3, 2038 | Pending
Australia | AU 2021367890 | May 3, 2022 | — | November 3, 2038 | Pending
New Zealand | NZ 789012 | May 3, 2022 | — | November 3, 2038 | Pending
Singapore | SG 11202204567X | May 2, 2022 | — | November 3, 2038 | Pending
Thailand | TH 2201001234 | May 3, 2022 | — | November 3, 2038 | Pending
Malaysia | MY PI2022002345 | May 3, 2022 | — | November 3, 2038 | Pending
Indonesia | ID P00202203456 | May 3, 2022 | — | November 3, 2038 | Pending
Philippines | PH 1-2022-550234 | May 2, 2022 | — | November 3, 2038 | Pending
Vietnam | VN 1-2022-02345 | May 3, 2022 | — | November 3, 2038 | Pending
Taiwan | TW 111116789 | May 2, 2022 | — | November 3, 2038 | Pending
Jurisdiction | Patent/Application No. | Filing Date | Grant Date | Expiration Date | Status
United States* | 17/456,789 | November 28, 2022 | — | May 28, 2039 | Pending
People's Republic of China | CN 202280023456.7 | November 25, 2022 | — | May 28, 2039 | Pending
Japan | JP 2023-572345 | November 28, 2022 | — | May 28, 2039 | Pending
Republic of Korea | KR 10-2023-7030123 | November 25, 2022 | — | May 28, 2039 | Pending
Australia | AU 2022278901 | November 28, 2022 | — | May 28, 2039 | Pending
New Zealand | NZ 801234 | November 28, 2022 | — | May 28, 2039 | Pending
Singapore | SG 11202212345A | November 25, 2022 | — | May 28, 2039 | Pending
Thailand | TH 2201003456 | November 28, 2022 | — | May 28, 2039 | Pending
Malaysia | MY PI2022006789 | November 28, 2022 | — | May 28, 2039 | Pending
Indonesia | ID P00202209012 | November 28, 2022 | — | May 28, 2039 | Pending
Philippines | PH 1-2022-551234 | November 25, 2022 | — | May 28, 2039 | Pending
Vietnam | VN 1-2022-05678 | November 28, 2022 | — | May 28, 2039 | Pending
Taiwan | TW 111143210 | November 25, 2022 | — | May 28, 2039 | Pending
Jurisdiction | Patent/Application No. | Filing Date | Grant Date | Expiration Date | Status
United States* | 17/512,345 | January 10, 2023 | — | July 12, 2039 | Pending
People's Republic of China | CN 202280034567.8 | January 8, 2023 | — | July 12, 2039 | Pending
Japan | JP 2024-501234 | January 10, 2023 | — | July 12, 2039 | Pending
Republic of Korea | KR 10-2024-7001234 | January 8, 2023 | — | July 12, 2039 | Pending
Australia | AU 2022312345 | January 10, 2023 | — | July 12, 2039 | Pending
New Zealand | NZ 812345 | January 10, 2023 | — | July 12, 2039 | Pending
Singapore | SG 11202300123W | January 8, 2023 | — | July 12, 2039 | Pending
Thailand | TH 2301000567 | January 10, 2023 | — | July 12, 2039 | Pending
Malaysia | MY PI2023000234 | January 10, 2023 | — | July 12, 2039 | Pending
Indonesia | ID P00202300456 | January 10, 2023 | — | July 12, 2039 | Pending
Philippines | PH 1-2023-550012 | January 8, 2023 | — | July 12, 2039 | Pending
Vietnam | VN 1-2023-00123 | January 10, 2023 | — | July 12, 2039 | Pending
Taiwan | TW 112100345 | January 8, 2023 | — | July 12, 2039 | Pending
Jurisdiction | Patent/Application No. | Filing Date | Grant Date | Expiration Date | Status
United States* | 17/534,567 | March 3, 2023 | — | September 3, 2039 | Pending
People's Republic of China | CN 202280045678.9 | March 1, 2023 | — | September 3, 2039 | Pending
Japan | JP 2024-512345 | March 3, 2023 | — | September 3, 2039 | Pending
Republic of Korea | KR 10-2024-7008901 | March 1, 2023 | — | September 3, 2039 | Pending
Australia | AU 2022345678 | March 3, 2023 | — | September 3, 2039 | Pending
New Zealand | NZ 823456 | March 3, 2023 | — | September 3, 2039 | Pending
Singapore | SG 11202301234Y | March 1, 2023 | — | September 3, 2039 | Pending
Thailand | TH 2301002345 | March 3, 2023 | — | September 3, 2039 | Pending
Malaysia | MY PI2023001567 | March 3, 2023 | — | September 3, 2039 | Pending
Indonesia | ID P00202301890 | March 3, 2023 | — | September 3, 2039 | Pending
Philippines | PH 1-2023-550345 | March 1, 2023 | — | September 3, 2039 | Pending
Vietnam | VN 1-2023-01456 | March 3, 2023 | — | September 3, 2039 | Pending
Taiwan | TW 112107890 | March 1, 2023 | — | September 3, 2039 | Pending
Jurisdiction | Patent/Application No. | Filing Date | Grant Date | Expiration Date | Status
United States* | 18/156,789 | July 12, 2023 | — | January 14, 2040 | Pending
People's Republic of China | CN 202380012345.0 | July 10, 2023 | — | January 14, 2040 | Pending
Japan | JP 2024-534567 | July 12, 2023 | — | January 14, 2040 | Pending
Republic of Korea | KR 10-2024-7018901 | July 10, 2023 | — | January 14, 2040 | Pending
Australia | AU 2023201234 | July 12, 2023 | — | January 14, 2040 | Pending
New Zealand | NZ 834567 | July 12, 2023 | — | January 14, 2040 | Pending
Singapore | SG 11202306789Z | July 10, 2023 | — | January 14, 2040 | Pending
Thailand | TH 2301005678 | July 12, 2023 | — | January 14, 2040 | Pending
Malaysia | MY PI2023004567 | July 12, 2023 | — | January 14, 2040 | Pending
Indonesia | ID P00202305678 | July 12, 2023 | — | January 14, 2040 | Pending
Philippines | PH 1-2023-551234 | July 10, 2023 | — | January 14, 2040 | Pending
Vietnam | VN 1-2023-04567 | July 12, 2023 | — | January 14, 2040 | Pending
Taiwan | TW 112125678 | July 10, 2023 | — | January 14, 2040 | Pending
Jurisdiction | Patent/Application No. | Filing Date | Grant Date | Expiration Date | Status
United States* | 18/189,012 | October 20, 2023 | — | April 22, 2040 | Pending
People's Republic of China | CN 202380034567.1 | October 18, 2023 | — | April 22, 2040 | Pending
Japan | JP 2024-545678 | October 20, 2023 | — | April 22, 2040 | Pending
Republic of Korea | KR 10-2024-7025678 | October 18, 2023 | — | April 22, 2040 | Pending
Australia | AU 2023245678 | October 20, 2023 | — | April 22, 2040 | Pending
New Zealand | NZ 845678 | October 20, 2023 | — | April 22, 2040 | Pending
Singapore | SG 11202309012B | October 18, 2023 | — | April 22, 2040 | Pending
Thailand | TH 2301008901 | October 20, 2023 | — | April 22, 2040 | Pending
Malaysia | MY PI2023007890 | October 20, 2023 | — | April 22, 2040 | Pending
Indonesia | ID P00202308901 | October 20, 2023 | — | April 22, 2040 | Pending
Philippines | PH 1-2023-552345 | October 18, 2023 | — | April 22, 2040 | Pending
Vietnam | VN 1-2023-07890 | October 20, 2023 | — | April 22, 2040 | Pending
Taiwan | TW 112138901 | October 18, 2023 | — | April 22, 2040 | Pending
Family No. | Family Description | Jurisdiction | Patent/Application No. | Filing Date | Grant Date | Expiration Date | Status | Assignee
1 | Composition of Matter | United States* | 11,234,567 | Jul. 15, 2019 | Jan. 25, 2022 | Aug. 12, 2037 | Granted | Penterra
1 | Composition of Matter | China | ZL 2020 1 0456789.0 | Jan. 14, 2020 | Sep. 8, 2023 | Aug. 12, 2037 | Granted | Penterra
1 | Composition of Matter | Japan | 7,012,345 | Jan. 15, 2020 | Jun. 23, 2023 | Aug. 12, 2037 | Granted | Penterra
1 | Composition of Matter | Republic of Korea | 10-2345678 | Jan. 14, 2020 | Aug. 4, 2023 | Aug. 12, 2037 | Granted | Penterra
1 | Composition of Matter | Australia | 2020234567 | Jan. 15, 2020 | Mar. 17, 2023 | Aug. 12, 2037 | Granted | Penterra
1 | Composition of Matter | New Zealand | 773456 | Jan. 15, 2020 | Jul. 28, 2023 | Aug. 12, 2037 | Granted | Penterra
1 | Composition of Matter | Singapore | 11202000456T | Jan. 14, 2020 | — | Aug. 12, 2037 | Pending | Penterra
1 | Composition of Matter | Thailand | 2001000345 | Jan. 15, 2020 | — | Aug. 12, 2037 | Pending | Penterra
1 | Composition of Matter | Malaysia | PI2020000789 | Jan. 15, 2020 | — | Aug. 12, 2037 | Pending | Penterra
1 | Composition of Matter | Indonesia | P00202000567 | Jan. 15, 2020 | — | Aug. 12, 2037 | Pending | Penterra
1 | Composition of Matter | Philippines | 1-2020-500123 | Jan. 14, 2020 | — | Aug. 12, 2037 | Pending | Penterra
1 | Composition of Matter | Vietnam | 1-2020-00234 | Jan. 15, 2020 | — | Aug. 12, 2037 | Pending | Penterra
1 | Composition of Matter | Taiwan | 109101234 | Jan. 14, 2020 | — | Aug. 12, 2037 | Pending | Penterra
2 | Crystalline Forms | United States* | 11,345,678 | Nov. 3, 2020 | May 16, 2023 | Nov. 3, 2038 | Granted | Penterra
2 | Crystalline Forms | China | CN 202180012345.6 | May 2, 2022 | — | Nov. 3, 2038 | Pending | Penterra
2 | Crystalline Forms | Japan | JP 2022-527891 | May 3, 2022 | — | Nov. 3, 2038 | Pending | Penterra
2 | Crystalline Forms | Republic of Korea | KR 10-2022-7013456 | May 2, 2022 | — | Nov. 3, 2038 | Pending | Penterra
2 | Crystalline Forms | Australia | AU 2021367890 | May 3, 2022 | — | Nov. 3, 2038 | Pending | Penterra
2 | Crystalline Forms | New Zealand | NZ 789012 | May 3, 2022 | — | Nov. 3, 2038 | Pending | Penterra
2 | Crystalline Forms | Singapore | SG 11202204567X | May 2, 2022 | — | Nov. 3, 2038 | Pending | Penterra
2 | Crystalline Forms | Thailand | TH 2201001234 | May 3, 2022 | — | Nov. 3, 2038 | Pending | Penterra
2 | Crystalline Forms | Malaysia | MY PI2022002345 | May 3, 2022 | — | Nov. 3, 2038 | Pending | Penterra
2 | Crystalline Forms | Indonesia | ID P00202203456 | May 3, 2022 | — | Nov. 3, 2038 | Pending | Penterra
2 | Crystalline Forms | Philippines | PH 1-2022-550234 | May 2, 2022 | — | Nov. 3, 2038 | Pending | Penterra
2 | Crystalline Forms | Vietnam | VN 1-2022-02345 | May 3, 2022 | — | Nov. 3, 2038 | Pending | Penterra
2 | Crystalline Forms | Taiwan | TW 111116789 | May 2, 2022 | — | Nov. 3, 2038 | Pending | Penterra
3 | Methods of Use | United States* | 17/456,789 | Nov. 28, 2022 | — | May 28, 2039 | Pending | Penterra
3 | Methods of Use | China | CN 202280023456.7 | Nov. 25, 2022 | — | May 28, 2039 | Pending | Penterra
3 | Methods of Use | Japan | JP 2023-572345 | Nov. 28, 2022 | — | May 28, 2039 | Pending | Penterra
3 | Methods of Use | Republic of Korea | KR 10-2023-7030123 | Nov. 25, 2022 | — | May 28, 2039 | Pending | Penterra
3 | Methods of Use | Australia | AU 2022278901 | Nov. 28, 2022 | — | May 28, 2039 | Pending | Penterra
3 | Methods of Use | New Zealand | NZ 801234 | Nov. 28, 2022 | — | May 28, 2039 | Pending | Penterra
3 | Methods of Use | Singapore | SG 11202212345A | Nov. 25, 2022 | — | May 28, 2039 | Pending | Penterra
3 | Methods of Use | Thailand | TH 2201003456 | Nov. 28, 2022 | — | May 28, 2039 | Pending | Penterra
3 | Methods of Use | Malaysia | MY PI2022006789 | Nov. 28, 2022 | — | May 28, 2039 | Pending | Penterra
3 | Methods of Use | Indonesia | ID P00202209012 | Nov. 28, 2022 | — | May 28, 2039 | Pending | Penterra
3 | Methods of Use | Philippines | PH 1-2022-551234 | Nov. 25, 2022 | — | May 28, 2039 | Pending | Penterra
3 | Methods of Use | Vietnam | VN 1-2022-05678 | Nov. 28, 2022 | — | May 28, 2039 | Pending | Penterra
3 | Methods of Use | Taiwan | TW 111143210 | Nov. 25, 2022 | — | May 28, 2039 | Pending | Penterra
4 | Pharmaceutical Formulations | United States* | 17/512,345 | Jan. 10, 2023 | — | Jul. 12, 2039 | Pending | Penterra
4 | Pharmaceutical Formulations | China | CN 202280034567.8 | Jan. 8, 2023 | — | Jul. 12, 2039 | Pending | Penterra
4 | Pharmaceutical Formulations | Japan | JP 2024-501234 | Jan. 10, 2023 | — | Jul. 12, 2039 | Pending | Penterra
4 | Pharmaceutical Formulations | Republic of Korea | KR 10-2024-7001234 | Jan. 8, 2023 | — | Jul. 12, 2039 | Pending | Penterra
4 | Pharmaceutical Formulations | Australia | AU 2022312345 | Jan. 10, 2023 | — | Jul. 12, 2039 | Pending | Penterra
4 | Pharmaceutical Formulations | New Zealand | NZ 812345 | Jan. 10, 2023 | — | Jul. 12, 2039 | Pending | Penterra
4 | Pharmaceutical Formulations | Singapore | SG 11202300123W | Jan. 8, 2023 | — | Jul. 12, 2039 | Pending | Penterra
4 | Pharmaceutical Formulations | Thailand | TH 2301000567 | Jan. 10, 2023 | — | Jul. 12, 2039 | Pending | Penterra
4 | Pharmaceutical Formulations | Malaysia | MY PI2023000234 | Jan. 10, 2023 | — | Jul. 12, 2039 | Pending | Penterra
4 | Pharmaceutical Formulations | Indonesia | ID P00202300456 | Jan. 10, 2023 | — | Jul. 12, 2039 | Pending | Penterra
4 | Pharmaceutical Formulations | Philippines | PH 1-2023-550012 | Jan. 8, 2023 | — | Jul. 12, 2039 | Pending | Penterra
4 | Pharmaceutical Formulations | Vietnam | VN 1-2023-00123 | Jan. 10, 2023 | — | Jul. 12, 2039 | Pending | Penterra
4 | Pharmaceutical Formulations | Taiwan | TW 112100345 | Jan. 8, 2023 | — | Jul. 12, 2039 | Pending | Penterra
5 | Manufacturing Process | United States* | 17/534,567 | Mar. 3, 2023 | — | Sep. 3, 2039 | Pending | Penterra
5 | Manufacturing Process | China | CN 202280045678.9 | Mar. 1, 2023 | — | Sep. 3, 2039 | Pending | Penterra
5 | Manufacturing Process | Japan | JP 2024-512345 | Mar. 3, 2023 | — | Sep. 3, 2039 | Pending | Penterra
5 | Manufacturing Process | Republic of Korea | KR 10-2024-7008901 | Mar. 1, 2023 | — | Sep. 3, 2039 | Pending | Penterra
5 | Manufacturing Process | Australia | AU 2022345678 | Mar. 3, 2023 | — | Sep. 3, 2039 | Pending | Penterra
5 | Manufacturing Process | New Zealand | NZ 823456 | Mar. 3, 2023 | — | Sep. 3, 2039 | Pending | Penterra
5 | Manufacturing Process | Singapore | SG 11202301234Y | Mar. 1, 2023 | — | Sep. 3, 2039 | Pending | Penterra
5 | Manufacturing Process | Thailand | TH 2301002345 | Mar. 3, 2023 | — | Sep. 3, 2039 | Pending | Penterra
5 | Manufacturing Process | Malaysia | MY PI2023001567 | Mar. 3, 2023 | — | Sep. 3, 2039 | Pending | Penterra
5 | Manufacturing Process | Indonesia | ID P00202301890 | Mar. 3, 2023 | — | Sep. 3, 2039 | Pending | Penterra
5 | Manufacturing Process | Philippines | PH 1-2023-550345 | Mar. 1, 2023 | — | Sep. 3, 2039 | Pending | Penterra
5 | Manufacturing Process | Vietnam | VN 1-2023-01456 | Mar. 3, 2023 | — | Sep. 3, 2039 | Pending | Penterra
5 | Manufacturing Process | Taiwan | TW 112107890 | Mar. 1, 2023 | — | Sep. 3, 2039 | Pending | Penterra
6 | Combination Therapy | United States* | 18/156,789 | Jul. 12, 2023 | — | Jan. 14, 2040 | Pending | Penterra
6 | Combination Therapy | China | CN 202380012345.0 | Jul. 10, 2023 | — | Jan. 14, 2040 | Pending | Penterra
6 | Combination Therapy | Japan | JP 2024-534567 | Jul. 12, 2023 | — | Jan. 14, 2040 | Pending | Penterra
6 | Combination Therapy | Republic of Korea | KR 10-2024-7018901 | Jul. 10, 2023 | — | Jan. 14, 2040 | Pending | Penterra
6 | Combination Therapy | Australia | AU 2023201234 | Jul. 12, 2023 | — | Jan. 14, 2040 | Pending | Penterra
6 | Combination Therapy | New Zealand | NZ 834567 | Jul. 12, 2023 | — | Jan. 14, 2040 | Pending | Penterra
6 | Combination Therapy | Singapore | SG 11202306789Z | Jul. 10, 2023 | — | Jan. 14, 2040 | Pending | Penterra
6 | Combination Therapy | Thailand | TH 2301005678 | Jul. 12, 2023 | — | Jan. 14, 2040 | Pending | Penterra
6 | Combination Therapy | Malaysia | MY PI2023004567 | Jul. 12, 2023 | — | Jan. 14, 2040 | Pending | Penterra
6 | Combination Therapy | Indonesia | ID P00202305678 | Jul. 12, 2023 | — | Jan. 14, 2040 | Pending | Penterra
6 | Combination Therapy | Philippines | PH 1-2023-551234 | Jul. 10, 2023 | — | Jan. 14, 2040 | Pending | Penterra
6 | Combination Therapy | Vietnam | VN 1-2023-04567 | Jul. 12, 2023 | — | Jan. 14, 2040 | Pending | Penterra
6 | Combination Therapy | Taiwan | TW 112125678 | Jul. 10, 2023 | — | Jan. 14, 2040 | Pending | Penterra
7 | Dosage Regimen | United States* | 18/189,012 | Oct. 20, 2023 | — | Apr. 22, 2040 | Pending | Penterra
7 | Dosage Regimen | China | CN 202380034567.1 | Oct. 18, 2023 | — | Apr. 22, 2040 | Pending | Penterra
7 | Dosage Regimen | Japan | JP 2024-545678 | Oct. 20, 2023 | — | Apr. 22, 2040 | Pending | Penterra
7 | Dosage Regimen | Republic of Korea | KR 10-2024-7025678 | Oct. 18, 2023 | — | Apr. 22, 2040 | Pending | Penterra
7 | Dosage Regimen | Australia | AU 2023245678 | Oct. 20, 2023 | — | Apr. 22, 2040 | Pending | Penterra
7 | Dosage Regimen | New Zealand | NZ 845678 | Oct. 20, 2023 | — | Apr. 22, 2040 | Pending | Penterra
7 | Dosage Regimen | Singapore | SG 11202309012B | Oct. 18, 2023 | — | Apr. 22, 2040 | Pending | Penterra
7 | Dosage Regimen | Thailand | TH 2301008901 | Oct. 20, 2023 | — | Apr. 22, 2040 | Pending | Penterra
7 | Dosage Regimen | Malaysia | MY PI2023007890 | Oct. 20, 2023 | — | Apr. 22, 2040 | Pending | Penterra
7 | Dosage Regimen | Indonesia | ID P00202308901 | Oct. 20, 2023 | — | Apr. 22, 2040 | Pending | Penterra
7 | Dosage Regimen | Philippines | PH 1-2023-552345 | Oct. 18, 2023 | — | Apr. 22, 2040 | Pending | Penterra
7 | Dosage Regimen | Vietnam | VN 1-2023-07890 | Oct. 20, 2023 | — | Apr. 22, 2040 | Pending | Penterra
7 | Dosage Regimen | Taiwan | TW 112138901 | Oct. 18, 2023 | — | Apr. 22, 2040 | Pending | Penterra
PCT Application No. | International Filing Date | Patent Family | Applicant | Status
PCT/US2019/045123 | July 15, 2019 | Family 1 — Composition of Matter | Penterra Pharmaceuticals Corp. | National phase entries completed; PCT application no longer pending
PCT/US2020/058901 | November 3, 2020 | Family 2 — Crystalline Forms | Penterra Pharmaceuticals Corp. | National phase entries completed; PCT application no longer pending
PCT/US2021/034567 | May 28, 2021 | Family 3 — Methods of Use | Penterra Pharmaceuticals Corp. | National phase entries completed; PCT application no longer pending
PCT/US2021/041234 | July 12, 2021 | Family 4 — Pharmaceutical Formulations | Penterra Pharmaceuticals Corp. | National phase entries completed; PCT application no longer pending
PCT/US2021/048901 | September 3, 2021 | Family 5 — Manufacturing Process | Penterra Pharmaceuticals Corp. | National phase entries completed; PCT application no longer pending
PCT/US2022/012345 | January 14, 2022 | Family 6 — Combination Therapy | Penterra Pharmaceuticals Corp. | National phase entries completed; PCT application no longer pending
PCT/US2022/025678 | April 22, 2022 | Family 7 — Dosage Regimen | Penterra Pharmaceuticals Corp. | National phase entries completed; PCT application no longer pending